Every 10-Q that iRadimed Corporation (IRMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IRMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IRMD filings page.
IRADIMED CORPORATION, a maker of MRI‑compatible infusion pumps and patient monitors, reported Q2 2026 revenue of $20.5 million, essentially flat year over year, with net income of $5.2 million and diluted EPS of $0.41 versus $0.45 a year earlier. Gross margin declined to 74% from 78%, mainly from initial production inefficiencies on new product manufacturing. U.S. revenue fell to $16.7 million while international revenue rose to $3.7 million. Device revenue decreased on lower IV pump sales, partly offset by higher patient monitoring and Ferro Magnetic Detection Systems, while disposables and service revenue grew. For the first six months, revenue increased to $42.4 million and net income to $11.0 million.
IRADIMED ended June 30, 2026 with $59.1 million in cash and cash equivalents, contract liabilities of $7.5 million tied largely to extended maintenance agreements, and stockholders’ equity of $101.7 million. Operating cash flow for the first half was $14.2 million, while capital spending moderated after prior facility expansion. Cash dividends declared for the first half totaled about $5.1 million, and a further quarterly dividend of $0.20 per share was approved for payment on August 28, 2026. Management expects higher full‑year 2026 revenue but also higher operating expenses, and reports no material legal matters or control weaknesses.
IRADIMED CORPORATION delivered solid growth in the first quarter of 2026. Revenue rose to $21.98 million from $19.51 million, driven mainly by stronger sales of MRI-compatible IV infusion pumps and patient monitoring systems, plus higher amortization of extended maintenance agreements.
Net income increased to $5.82 million, or $0.45 per diluted share, compared with $4.69 million, or $0.37 per diluted share, helped by a 77% gross margin and disciplined operating expenses. Cash and cash equivalents grew to $56.37 million, and the company continued returning capital through dividends, with a $0.20 per share quarterly dividend declared for payment in May 2026.
IRADIMED CORPORATION reported solid growth for the quarter ended September 30, 2025, with revenue of $21.2 million, up 16% year over year. Net income was $5.6 million and diluted EPS was $0.43. Gross margin improved to 78% as device sales led results, including MRI-compatible IV infusion pumps at $8.3 million and patient monitoring systems at $6.9 million. U.S. revenue grew 19% to $18.1 million, while international revenue was $3.1 million.
Operating income rose to $6.8 million as operating expenses increased with higher sales activity and payroll. Cash and cash equivalents were $56.5 million, and contract liabilities rose to $6.7 million, reflecting growth in maintenance agreements and advance customer payments. The company completed its new Orlando facility and announced FDA 510(k) clearance for the next‑generation MRidium 3870, with an initial rollout planned in Q4 2025. The Board declared a regular cash dividend of $0.17 per share, payable November 25, 2025 to holders of record on November 14, 2025. Shares outstanding were 12,721,156 as of October 31, 2025.